Title: Updates in Treatment for HR+/HER2- Metastatic Breast Cancer
Time: 25th February 3pm – 4pm
Speaker: Dr. Komal Jhaveri, Medical Oncologist, Memorial Sloan Kettering , New York
PP-IBR-IRL-0392 Date of Preparation February 2021
Please click here for the ▼IBRANCE® Summary of Product Characteristics. IBRANCE® is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: -in combination with an aromatase inhibitor; -in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.1 of SmPC). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.1
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SmPC for how to report adverse reactions.
References: IBRANCE® (Palbociclib) Summary of Product Characteristics
Legal Category: S1A
This educational meeting/event is hosted by Combined Media on behalf of Pfizer Healthcare Ireland. Your name and email address is required for us to take attendance and for you to register and join the event. We will never use your name or email address for any marketing purposes. Please see the Webinar Now Privacy Notice for more details on how Combined Media manages your personal data.
Please see link to the Pfizer Privacy Notice: https://privacycenter.pfizer.com/en/ireland.
By receiving this invitation from Pfizer for attendance at this virtual event, you agree, click here for more details